Semaglutide Regulatory Status in Canada Health Canada Approval Status (Ozempic, Wegovy, Rybelsus, Generic) Semaglutide is the active ingredient in three Novo Nordisk products authorized for sale in Canada: Ozempic (authorized 2018 for type 2 diabetes, with an expanded indication in 2024 to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes), Rybelsus (oral semaglutide tablets authorized for type 2 diabetes), and Wegovy (authorized 2021 for chronic weight management, with an expanded indication in 2024 to reduce the risk of non-fatal myocardial infarction, and a Notice of Compliance with Conditions issued in December 2025 for non-cirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis)
Many patients report feeling more mentally sharp and energetic as their bodies adapt to a healthier weight
What Retatrutide Is and How Dosing Works Retatrutide is an investigational peptide that targets multiple metabolic pathways involved in appetite, digestion, and energy balance
Angiology 69 , 288296 (2017)
doi: 10.5055/jom.2010.0043
Asthma exacerbations in individuals on glucagon-like peptide-1 receptor agonists for type 2 diabetes